Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Protara Therapeutics, Inc. (TARA) had Return on Tangible Equity of -29.24% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-57.44M |
|
-- |
|
-- |
|
$64.55M |
|
$-64.55M |
|
$7.11M |
|
$-57.44M |
|
$-57.44M |
|
$-57.44M |
|
$-57.44M |
|
$-57.44M |
|
$-57.44M |
|
$-64.55M |
|
$-65.43M |
|
42.84M |
|
42.84M |
|
$-1.34 |
|
$-1.34 |
|
| Balance Sheet Financials | |
$159.50M |
|
$0.76M |
|
$49.96M |
|
$209.47M |
|
$10.94M |
|
-- |
|
$2.12M |
|
$13.06M |
|
$196.41M |
|
$196.41M |
|
$196.41M |
|
53.59M |
|
| Cash Flow Statement Financials | |
$-56.37M |
|
$-139.49M |
|
$82.72M |
|
$163.54M |
|
$50.40M |
|
$-113.14M |
|
$3.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-56.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-29.24% |
|
|
Return on Tangible Equity |
-29.24% |
-27.42% |
|
-29.24% |
|
$3.67 |
|
$-1.32 |
|
$-1.32 |
|